Successful treatment of HCV‐related glomerulonephritis with sofosbuvir and daclatasvir

Chia, Xiu Xian; Cherepanoff, Svetlana; Danta, Mark; Furlong, Tim

doi:10.1111/nep.13087

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He achieved SVR with glomerular filtration rate and proteinuria improvement, allowing antihypertensive and diuretic suspension. However, the patient persisted with cryoglobulinemia and microscopic hematuria 15 .…”

Section: Discussionmentioning

confidence: 94%

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy

et al. 2021

View full text Add to dashboard Cite

In addition to liver disease, the hepatitis C virus (HCV) has been associated with autoimmune phenomena, such as mixed cryoglobulin and glomerulonephritis (GN). Until recently, both chronic hepatitis and HCV extra-hepatic manifestations were treated with peg-interferon plus ribavirin, however these drugs presented low efficacy and induced severe side effects. Nowadays, the HCV chronic hepatitis has been treated with direct acting antivirals (DAA), but studies on the DAA therapy for HCV-associated glomerulonephritis are scarce. Here, we describe two cases of HCV-associated glomerulonephritis that were treated with DAAs. In these two cases, previously experienced to peg-interferon plus ribavirin, the sofosbuvir plus simeprevir therapy was effective, without significant side effects, and interrupted the evolution of at least 20 years of both hepatic and renal diseases. These cases join the seven previously described cases that were treated with this DAAs association.

show abstract

Section: Discussionmentioning

confidence: 94%

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition to the studies reported above, small patient series (reviewed in [29]) and some case reports have been published. At our knowledge, at least 11 patients with HCV-associated glomerular disease experienced clinical benefit after completing therapy with DAAs [29][30][31][32][33][34].…”

Section: Antiviral Treatment Of Hcv (Daas) For Hcv-related Glomerularmentioning

confidence: 99%

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence

et al. 2019

View full text Add to dashboard Cite

Glomerular disease is an extra-hepatic manifestation of hepatitis C virus infection (HCV) and membranoproliferative glomerulonephritis is the most frequent glomerular disease associated with HCV. It occurs commonly in patients with HCV-related mixed cryoglobulinemia syndrome. Patients with HCV-related glomerular disease have been historically a difficult-to-treat group. The therapeutic armamentarium for HCV-related glomerular disease now includes antiviral regimens, selective or non-specific immunosuppressive drugs, immunomodulators, and symptomatic agents. The treatment of HCV-associated glomerular disease is dependent on the clinical presentation of the patient. The recent introduction of all-oral, interferon (IFN)-free/ribavirin (RBV)-free regimens is dramatically changing the course of HCV in the general population, and some regimens have been approved for HCV even in patients with advanced chronic kidney disease. According to a systematic review of the medical literature, the evidence concerning the efficacy/safety of direct-acting antiviral agents (DAAs) of HCV-induced glomerular disease is limited. The frequency of sustained virological response was 92.5% (62/67). Full or partial clinical remission was demonstrated in many patients (n = 46, 68.5%) after DAAs. There were no reports of deterioration of kidney function in patients on DAAs. Many patients (n = 29, 43%) underwent immunosuppression while on DAAs. A few cases of new onset or relapsing glomerular disease in patients with HCV successfully treated with DAAs have been observed. In summary, DAA-based combinations are making easier the management of HCV. However, patients with HCV-induced glomerular disease are still a difficult-to-treat group even at the time of DAAs.

show abstract

Successful treatment of HCV‐related glomerulonephritis with sofosbuvir and daclatasvir

Cited by 2 publications

References 3 publications

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence

Contact Info

Product

Resources

About